WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2002032461) PROTEIN C OR ACTIVATED PROTEIN C-LIKE MOLECULES
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2002/032461    International Application No.:    PCT/DK2001/000679
Publication Date: 25.04.2002 International Filing Date: 15.10.2001
Chapter 2 Demand Filed:    27.04.2002    
IPC:
C12N 9/64 (2006.01)
Applicants: MAXYGEN APS [DK/DK]; 1 Agern Allé, DK-2970 Hørsholm (DK).
MAXYGEN HOLDINGS LTD. [--/--]; 515 Galveston Drive, Redwood City, CA 94063 (US)
Inventors: ANDERSEN, Kim, Vilbour; (DK).
PEDERSEN, Anders, Hjelholt; (DK).
FRESKGAARD, Per, Ola; (SE)
Common
Representative:
MAXYGEN APS; Agern Allé 1, DK-2970 Hørsholm (DK)
Priority Data:
PA 2000 01560 18.10.2000 DK
60/242,268 18.10.2000 US
PA 2001 00970 21.06.2001 DK
60/300,154 21.06.2001 US
Title (EN) PROTEIN C OR ACTIVATED PROTEIN C-LIKE MOLECULES
(FR) MOLECULES DE PROTEINE C OU DE TYPE PROTEINE C ACTIVEE
Abstract: front page image
(EN)The present invention relates to novel conjugates between polypeptide variants of pro-tein C and a non-polypeptide moiety, such as PEG or sugar moieties. In particular, the present invention provides novel protein C conjugates having an increased resistance to inactivation by e.g. human plasma and a1-antitrypsin. Consequently, such conjugates have an increased in vivo half-life. Preferred examples include protein C conjugates, wherein at least one additional in vivo N-glycosylation site has been introduced. The conjugates of the invention are useful for treating a variety of diseases, including septic shock.
(FR)La présente invention a trait à de nouveaux conjugués entre des variants polypeptidiques de protéine C et une fraction non polypeptidique, telle qu'une fraction PEG ou des fractions de sucre. L'invention concerne en particulier de nouveaux conjugués de protéine C présentant une résistance accrue à l'inactivation par le plasma humain ou l'$g(a)¿1?-antitrypsine par exemple. Par conséquent, de tels conjugués ont une demi-vie in vivo prolongée. Des exemples préférés comportent des conjugués de protéine C, dans lesquels au moins un site de N-glycosylation in vivo supplémentaire a été introduit. Les conjugués selon l'invention sont utiles dans le traitement de maladies diverses, notamment du choc septique.
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
African Regional Intellectual Property Organization (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)